Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-154 in Glucocorticoid-Dependent Polymyalgia Rheumatica
NCT04972968Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2021
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of ABBV-154 in polymyalgia rheumatica (PMR) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Time to Flare at Week 52. Started Sep 2021; status: terminated.
02
Drugs
ABBV-154
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT04972968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972968.